<p>G-protein-coupled receptors (GPCRs) are key mediators of cell communication and represent the most important class of drug targets<sup><CitationRef CitationID="CR1">1</CitationRef>,<CitationRef CitationID="CR2">2</CitationRef></sup>. Biophysical studies with purified GPCRs in vitro have suggested that they exist in an equilibrium of distinct inactive and active states, which is modulated by ligands in an efficacy-dependent manner<sup><CitationRef AdditionalCitationIDS="CR4 CR5 CR6 CR7 CR8 CR9 CR10" CitationID="CR3">3</CitationRef>–<CitationRef CitationID="CR11">11</CitationRef></sup>. However, how efficacy is encoded and whether multiple receptor states occur in living cells remain unclear. Here we use genetic code expansion<sup><CitationRef CitationID="CR12">12</CitationRef></sup> and bioorthogonal labelling<sup><CitationRef AdditionalCitationIDS="CR14 CR15" CitationID="CR13">13</CitationRef>–<CitationRef CitationID="CR16">16</CitationRef></sup> to generate a panel of fluorescence-based biosensors for a prototypical GPCR, the M<sub>2</sub> muscarinic acetylcholine receptor (M<sub>2</sub>R). These biosensors enable real-time monitoring of agonist-promoted conformational changes across the receptor’s extracellular surface in intact cells. We demonstrate that different agonists produce equilibria of at least four distinct active states of the G-protein-bound M<sub>2</sub>R, each with a different ability to activate G proteins. The formation of these M<sub>2</sub>R–G-protein complexes occurs over 0.2–5 s along trajectories that involve both common and ligand-specific conformational changes and appear to determine G-protein selectivity. These observations reveal the molecular nature of ligand efficacy in intact cells. Selectively exploiting such different GPCR activation trajectories and conformational equilibria may open new avenues for GPCR drug discovery.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Ligand-specific activation trajectories dictate GPCR signalling in cells

  • Romy Thomas,
  • Pauline S. Jacoby,
  • Chiara De Faveri,
  • Cécile Derieux,
  • Aenne-Dorothea Liebing,
  • Barbora Melkes,
  • Hans-Joachim Martini,
  • Marcel Bermúdez,
  • Claudia Stäubert,
  • Martin J. Lohse,
  • Irene Coin,
  • Andreas Bock

摘要

G-protein-coupled receptors (GPCRs) are key mediators of cell communication and represent the most important class of drug targets1,2. Biophysical studies with purified GPCRs in vitro have suggested that they exist in an equilibrium of distinct inactive and active states, which is modulated by ligands in an efficacy-dependent manner311. However, how efficacy is encoded and whether multiple receptor states occur in living cells remain unclear. Here we use genetic code expansion12 and bioorthogonal labelling1316 to generate a panel of fluorescence-based biosensors for a prototypical GPCR, the M2 muscarinic acetylcholine receptor (M2R). These biosensors enable real-time monitoring of agonist-promoted conformational changes across the receptor’s extracellular surface in intact cells. We demonstrate that different agonists produce equilibria of at least four distinct active states of the G-protein-bound M2R, each with a different ability to activate G proteins. The formation of these M2R–G-protein complexes occurs over 0.2–5 s along trajectories that involve both common and ligand-specific conformational changes and appear to determine G-protein selectivity. These observations reveal the molecular nature of ligand efficacy in intact cells. Selectively exploiting such different GPCR activation trajectories and conformational equilibria may open new avenues for GPCR drug discovery.